Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison.

BMC Cancer
Stefania RedanaFilippo Montemurro

Abstract

Combinations of trastuzumab with either docetaxel or vinorelbine are considered valuable treatment options for HER2-positive metastatic breast cancer patients. We performed a retrospective comparison of the clinical outcomes associated with either one of these combinations. From a multi-institutional database we retrieved 179 patients treated with either docetaxel or vinorelbine plus trastuzumab as first-line therapy for HER2-positive advanced breast cancer. Docetaxel-trastuzumab was superior to vinorelbine-trastuzumab in terms of response rate (RR: 77 vs 57%, p = 0.01) and median overall survival (OS: 35 vs 23 months, p = 0.04), but not in median time to progression (TTP: 12 vs 10 months, p = 0.53). At multivariate analysis, type of treatment was not associated with TTP but was an independent predictor of OS, with a significant reduction in the risk of death in favor of docetaxel-trastuzumab (HR 0.474, 95% IC 0,303-0.742, p < 0.01). Docetaxel or vinorelbine, when combined with trastuzumab, provide excellent rates of tumor control in patients with previously untreated HER2-positive advanced breast cancer. Docetaxel may offer some advantage in terms of response rate and resulted in a significantly prolonged overall survival, whi...Continue Reading

References

Jan 1, 1981·Cancer·A B MillerA Winkler
Jan 1, 1995·Investigational New Drugs·D J Adams, V C Knick
Jul 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P FumoleauM T Closon
May 16, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H J BursteinE P Winer
Feb 15, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A DepierreV Trillet-Lenoir
Dec 19, 2003·Expert Opinion on Pharmacotherapy·Filippo MontemurroMassimo Aglietta
May 20, 2004·Journal of the National Cancer Institute·Mark D PegramDennis J Slamon
Oct 21, 2005·The New England Journal of Medicine·Martine J Piccart-GebhartUNKNOWN Herceptin Adjuvant (HERA) Trial Study Team
Oct 21, 2005·The New England Journal of Medicine·Edward H RomondNorman Wolmark
Feb 24, 2006·The New England Journal of Medicine·Heikki JoensuuUNKNOWN FinHer Study Investigators
Feb 1, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A Chan
Sep 12, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C CataniaF Nolè

❮ Previous
Next ❯

Citations

Sep 13, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A AwadaE Staroslawska
Jan 17, 2013·The Breast Journal·Ying-Chun XuFeng-Chun Zhang
May 17, 2018·Anais Da Academia Brasileira De Ciências·Luma G MagalhaesAdriano D Andricopulo
Jan 13, 2021·Cancers·Faruque Azam, Alexei Vazquez

❮ Previous
Next ❯

Methods Mentioned

BETA
Fluorescence

Software Mentioned

SPSS
HercepTest

Related Concepts

Related Feeds

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.